29.07.2021 / Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 (Lancet ID): https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00420-5/fulltext
27.05.2021 / Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS) (The Lancet, Preprint): https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3854768